Drug intelligence / Profile preview

BX-U007

Development stage: Preclinical
Lead developer: Baylx
Modality: Stem Cell Therapies → Cell Therapies

Overview

BX-U007 is a stem cell therapy under development by Baylx for the treatment of nervous system diseases, with its primary indication being cerebral palsy. The drug's mechanism of action is described as "cell replacements," indicating that it aims to replace or repair damaged or dysfunctional cells in the nervous system through stem cell transplantation. As of March 2025, BX-U007 remains in preclinical development and has not yet entered clinical trials.

Beyond the preview

Go deeper on BX-U007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BX-U007.